CLINICAL & PATIENT EDUCATORS ASSOCIATION

**Title:** Clinical Issues in Type 2 Diabetes and Debates Around GLP-1 Receptor Agonists
**Dates:** Live symposia held June 6, 2015 and online (expiring September 10, 2016)
**Locations:** Boston, Massachusetts
Online: http://www.medscape.org/viewarticle/848124

## Learning Objectives

*After completing this activity, the participant should be better able to:*

- Describe the relative benefits and risks of GLP-1 receptor agonists versus other oral and injectable antidiabetes medications
- Select among available short- and long-acting GLP-1 receptor agonists when intensifying T2DM therapy for various patient types
- Tailor combination regimens that include GLP-1 receptor agonists and other antihyperglycemic agents based on disease severity, comorbidities, and risks of hypoglycemia
- Engage in open dialogues with patients about the clinical profiles of GLP-1 receptor agonists and treatment adherence

## Target Audience

The educational design of this activity addresses the needs of endocrinologists and other health care providers involved in the treatment of patients with type 2 diabetes.

## Program Overview

Over the last decade, increased understanding of the pathophysiology of type 2 diabetes mellitus (T2DM) has aided the development of new and expanding classes of antihyperglycemic medications. Agonists of glucagon-like peptide-1 (GLP-1) receptors, for example, take advantage of incretin hormone signaling to induce glucose-independent insulin release from pancreatic βcells, reduce hepatic glucose production, slow gastric emptying, and increase satiety. The potential benefits and risks of GLP-1 receptor agonists for various patient types or complicating comorbidities are the subjects of much ongoing clinical research. Indeed, education on how to achieve individualized glycemic targets and appropriately use these medications is of great practical interest to endocrinologists and other health care providers. This Clinical Issues™ program will provide attendees at the 2015 Scientific Sessions of the American Diabetes Association with scientifically rigorous, clinically accurate, and highly applicable recommendations for the roles of GLP-1 receptor agonists in multimodal T2DM management.

## Faculty

Lawrence Blonde, MD, FACP, FACE
Director, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, Louisiana

Jaime A. Davidson, MD, FACP, MACE
Clinical Professor of Medicine
Touchstone Diabetes Center
University of Texas
Southwestern Medical Center
Dallas, Texas

Daniel Einhorn, MD, FACP, FACE
Clinical Professor of Medicine
University of California, San Diego
Diabetes and Endocrine Associates
Medical Director
Scripps Whittier Diabetes Institute
La Jolla, California

**Physician Accreditation Statement**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and Integritas Communications, LLC. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

**Physician Credit Designation**

Clinical and Patient Educators Association designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical and Patient Educators Association designates this enduring material for a maximum of 1.0 *AMA PRA Category 1 Credit*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure of Conflicts of Interest**

CPEA requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

**Commercial Support**

This activity is supported by an educational grant from AstraZeneca.